Spring Creek Capital’s Tevogen Bio Warrant TVGNW Stock Holding History

Spring Creek Capital’s Portfolio TVGNW Stock Details TVGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-150,000	Closed	-$41K	–	85
2022 Q1	$41K	Buy	+150,000	New	+$55.8K	﹤0.01%	594

Other funds holding TVGNW

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Verition Fund Management

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Parallax Volatility Advisers

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Spring Creek Capital's TVGNW Position: Q2 2022 in Review

Spring Creek Capital sold out of Tevogen Bio Warrant (TVGNW) in Q2 2022, closing a stake of 150,000 shares — an estimated $41K sold.

Spring Creek Capital first reported a position in TVGNW in Q1 2022 and held it in 1 quarter. The position peaked at $41K in Q1 2022. 46 funds tracked by Wall St. Rank hold TVGNW as of Q2 2022.

Spring Creek Capital reported no remaining Tevogen Bio Warrant position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 150,000 Tevogen Bio Warrant shares in Q2 2022, an estimated $41K.
Spring Creek Capital first reported a position in Tevogen Bio Warrant in Q1 2022 and held it in 1 quarter.
Spring Creek Capital's Tevogen Bio Warrant position peaked at $41K in Q1 2022.
46 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.